Status:
COMPLETED
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Lead Sponsor:
Maimónides Biomedical Research Institute of Córdoba
Collaborating Sponsors:
Junta de Andalucia
Dynamic Solutions
Conditions:
SARS-CoV 2
COVID19
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
The administration of Calcifediol in patients with COVID-19, will reduce the development of SARS and the worsening of the various phases of the syndrome. Reducing at least 25% in ICU admission and dea...
Eligibility Criteria
Inclusion
- Age ≥ 18 and \< 90 years
- PCR confirmed diagnosis of COVID-19. As an alternative to PCR, a determination of antigens or any other test that in the future is considered equivalent to these in its diagnostic value may be accepted as evidence
- Radiological image compatible with inflammatory pleuropulmonary exudate or patients with onset of symptoms in the last 7 days and with an uncomplicated respiratory infection for outpatient follow-up.
- Signature of direct or delegated informed consent
Exclusion
- Being treated with Calcifediol or Cholecalciferol in any of its presentations and dosages
- Intolerance or allergy to Calcifediol or its components
- Pregnancy
Key Trial Info
Start Date :
May 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 19 2022
Estimated Enrollment :
517 Patients enrolled
Trial Details
Trial ID
NCT04366908
Start Date
May 7 2020
End Date
April 19 2022
Last Update
March 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Reina Sofía
Córdoba, Spain, 14001